Bicara Therapeutics Inc. Common Stock

BCAX

$20.49

Updated: 24/09/2026, 10:43:58

Market Cap

$1.35B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for BCAX

Company Profile

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

USD

NASDAQ

CEO: Claire Mazumdar Clemon

Employees: 103

https://www.bicara.com

Asset Summaries

Latest generated summaries for BCAX

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for BCAX.

Share price: $20.49
Market cap: $1.35B
Exchange: NASDAQ
Currency: USD
CEO: Claire Mazumdar Clemon
Employees: 103
IPO date: 13/09/2024
Beta: -0.8159999999999999
Last dividend: $0.00
Day range: $20.48 – $23.12
52-week range: $10.48 – $30.99
1-day performance: -10.07%
1-year performance: 95.47%
Current drawdown (1Y): -33.90%
CIK: 0002023658
CUSIP: 055477103
ISIN: US0554771032
Created: 07/12/2025, 02:56:19
Last update: 24/09/2026, 10:43:58

Track Bicara Therapeutics Inc. Common Stock with an AI analyst

See which prediction-market events move BCAX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to BCAX from your Railway `news_articles` table.

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?

The Motley Fool • STOCK • 13/06/2026, 03:01:24

Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript

Seeking Alpha • STOCK • 22/05/2026, 14:50:43

Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

MarketBeat • STOCK • 22/05/2026, 13:10:07

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

GlobeNewsWire • STOCK • 21/05/2026, 19:00:00

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

MarketBeat • STOCK • 14/05/2026, 19:10:44

Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 13/05/2026, 17:00:55

Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 11/05/2026, 14:00:44

Bicara Therapeutics Q1 Earnings Call Highlights

MarketBeat • STOCK • 11/05/2026, 12:07:28

Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade

Zacks Investment Research • STOCK • 01/04/2026, 12:55:17

Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement

Seeking Alpha • STOCK • 31/03/2026, 17:34:27

Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call Transcript

Seeking Alpha • STOCK • 30/03/2026, 14:32:04

Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

GlobeNewsWire • STOCK • 30/03/2026, 09:30:00